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ABSTRACT
Introduction: Pulmonary arterial hypertension (PAH) is a low prevalence condition for which there is very
little information in Peru. Several studies indicate that it is associated with elevated costs for health systems
in the world. Objective: To establish the economic burden of PAH in the Peruvian context. Methods:
Information on the use of health resources was collected through consultations with clinical experts
and key opinion leaders. Cost data was obtained from two tariff manuals and from the Observatory of
Pharmaceutical Products (DIGEMID). Results: Expert consultations indicated that about 68% of the
patients were in an intermediate stage of the disease and that the use of sequential combination therapy
is predominant in FC III and FC IV stages, compared to earlier stages. The annual cost of PAH treatment
in Peru was $ 14,842 USD, where the main cost driver was drugs (81.72%), followed by diagnosis (8.96%)
and outpatient follow-up (5.75%). Conclusions: Information on pulmonary arterial hypertension in Peru
is critical for decision makers, due to the high economic impact that the disease entails. Moreover, studies
in this therapeutic area are relevant for the dissemination of knowledge of the disease to different health
professionals.
Key words: Pulmonary Arterial Hypertension; Cost of Illness; Peru (source: MeSH NLM).

RESUMEN
Introducción: La hipertensión arterial pulmonar (HAP) es una condición de baja prevalencia para la que
existe muy poca información en el Perú. Diversos estudios indican que genera costos importantes para
los sistemas de salud en el mundo. Objetivo: Establecer la carga económica de la HAP en el contexto
peruano. Métodos: La información de uso de recursos en salud se recolectó por medio de consultas a
expertos clínicos y líderes de opinión. La información de costos fue obtenida de dos manuales tarifarios
y del Observatorio de Productos farmacéuticos. Resultados: Los expertos indicaron que alrededor del
68% de los pacientes se encontraban en un estadio intermedio de la enfermedad y que el uso de terapia
combinada secuencial es predominante en los estados FC III y FC IV, en comparación con estadios más
tempranos. El costo de tratamiento anual de la HAP en el Perú fue de $14.842 USD (S/ 25.885), donde
el principal rubro fueron los medicamentos (81,72%), seguido del diagnóstico (8,96%) y seguimiento
ambulatorio (5,75%). Conclusión: La información sobre la hipertensión arterial pulmonar en el Perú
es crítica para los tomadores de decisión, debido al alto impacto económico que conlleva. Más aún,
estudios en esta área terapéutica son relevantes para la difusión del conocimiento de la enfermedad a
los diferentes profesionales de la salud.
Palabras clave: Hipertensión Arterial Pulmonar; Costo de Enfermedad; Perú (fuente: DeCS BIREME).
1 IQVIA Colombia – Bogotá, Colombia.
2
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3
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4
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INTRODUCTION

METHODS

Pulmonary hypertension groups have different low
prevalence conditions that have a similar clinical
presentation. It is defined as a mean pulmonary
arterial pressure greater than 25 mmHg at rest and
greater than 30 mmHg during exercise. Among the
conditions grouped by pulmonary hypertension,
pulmonary arterial hypertension (PAH) stands
out, which, in addition to the previous criteria, is
characterized by a wedge pressure of the pulmonary
artery less than 15 mmHg(1,2). The increase in pressure
is mainly caused by an increase in the vascular
resistance of the pulmonary arteries that can have
genetic, environmental, or idiopathic etiology;
therefore, the risk factors for the development of
PAH are related to genetic mutations (especially in
the BMPR2 gene)(3), congenital heart problems(4),
living in high altitude regions(5) and the consumption
of some drugs or substances(6).

Design and study area

Since the diagnosis of PAH usually requires
active screening of patients with risk factors and
preexistence(10), and that the pharmacological
treatments indicated for this condition are
expensive(11), the burden imposed on the health of
the system is considerable. In this sense, a systematic
review of cost studies in PAH found that the monthly
cost per patient per month varies between the
US $ 2,476 and $ 11,875, where the costs related
to pharmacological treatment and medical care
were the key sources of direct medical costs(12).
Similarly, some studies have estimated that there
are significant differences in the cost of the disease
by Functional Classification (FC) of the World Health
Organization (WHO)(13), so it becomes relevant to
know this economic burden within the Peruvian
health system.
The objective of the present study was to estimate
the economic burden associated with the diagnosis,
treatment, and follow-up of PAH from the perspective
of the Peruvian third-party payer.
https://inicib.urp.edu.pe/rfmh/vol21/iss3/16
DOI: https://doi.org/10.25176/RFMH.v21i3.3905

Population and sample
The universe of patients covered by these specialists
was 186 patients during 16 years of clinical practice.

Variables and instruments
The analysis variables are the costs related to the
events associated with PAH. Information collection
instruments were developed based on the proposed
objectives, which guided the conduct of the
interviews. These were intended to identify the use
of resources and relevant cost-generating events in
the treatment of patients with a diagnosis of PAH
from the perspective of the Peruvian third-party
payer, in this case, MINSA and EsSalud only those
that generated costs were considered to direct
physicians.

ORIGINAL PAPER

Currently, there is no information on the prevalence
or incidence of PAH in Peru. However, the prevalence
of this disease in high-income countries is estimated
to be between 5 and 52 cases per million inhabitants,
with an incidence of 2.5 to 7.1 new cases per million
inhabitants(7). Given its low prevalence, this disease
has been classified as an orphan disease, according
to Ministerial Resolution 1075 of 2019 of the Ministry
of Health of Peru, so its care and treatment are
guaranteed by the national government(8,9).

This study was based on in-depth interviews with four
cardiologists with experience in the management of
PAH in reference centers in Peru.

Procedures
The study consists of two phases: the first consists
of interviews with clinical experts to determine
the management of PAH; the second focuses on
the performance of microcosting related to events
associated with PAH. The approach followed both
in the interviews and in the cost estimation is
summarized below.

Identification of resources and cost-generating
events
The four cardiologists were consulted regarding
five relevant aspects of these patients’ health care:
diagnosis, drug treatment, outpatient followup, in-hospital care, and adverse events (AE). The
questionnaires that guided the interviews were
prepared based on the guidelines of the European
Society of Cardiology (ESC) and the European
Respiratory Society (ERS) for the treatment of
PAH (14). Similarly, the experts were questioned
regarding the functional classification of the patients
they treated and its etiology.

Cost estimation
Each resource and the cost-generating event was
assigned a price-weighted by the frequency of use
and the proportion of patients to which each was
prescribed to estimate the total cost of PAH in Peru per
Pág. 581
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patient per year. This approach is called microcosting,
and its use is common in economic evaluations(15).
In Peru, the sources of costs for procedures and
consultations were the rate manuals of the National
Institute of Neoplastic Diseases and the Cayetano
Heredia Hospital(16,17). For drugs, the database of the
Pharmaceutical Products Observatory (DIGEMID /
MINSA) was consulted Statistical analysis.
The final cost of the disease was expressed in
United States dollars (USD) adjusted for Purchasing
Power Parity (PPP), which allows the comparison
of the acquisition of goods and services between
different economies since this value is less sensitive
to changes in supply and demand. In this study, the
conversion rate of the Peruvian sol to USD PPP for
2018 was used, which is equivalent to S / 1,744 for
each USD.

Ethical consideration
This study did not require intervention in humans, so
there is no need for review by an ethics committee.

RESULTS
DWithin the universe of patients comprised by the
cardiologists interviewed, it was evidenced that
63.7% of patients with PAH had a diagnosis associated
with congenital heart disease, 20.8% corresponded
to patients with a disease of idiopathic etiology, and
8.5% of the patients had a disease associated with
connective tissue disorders. On the other hand, the
experts consulted indicated that they stratified the
patients mainly by functional class, showing that
68% of them were in intermediate stages of disease
severity (32% in FC II and 36% in FC III). In contrast,
15% and 16% of patients were in FC I and FC IV
states, respectively.
In general, the report on the use of resources
(procedures and laboratories) for the diagnosis of
PAH was quite homogeneous among the experts
interviewed, generating an average annual cost of
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diagnosis of $ 1,329.9 per patient. Regarding the
cost of outpatient follow-up, the use of resources
was more heterogeneous among specialists, and
its total annual cost was $ 852.9 per patient. On the
other hand, the annual cost of non-pharmacological
treatment and adverse events corresponded to $
276.4 and $ 1.10, respectively (Table 1).
Regarding hospitalizations and length of hospital
stay, the experts consulted indicated that
patients in FC I and II states usually do not report
hospitalizations or admissions to the Intensive Care
Unit (ICU); therefore, they do not incur costs related
to this item. In contrast, FC III and FC IV patients
spend an average of 12 and 14 days a year in the
general hospitalization room and 7 and 7.5 days a
year in the ICU, respectively. The cost of the general
inpatient ward stay is $ 595.5 and $ 693.1 for FC III
and FC IV patients, respectively. The cost of staying
in the ICU is 1,404.6 and 1,490.7, respectively.
Regarding pharmacological treatment, it was
evidenced that sequential combination therapy is
predominant in the FC III and FC IV states. In contrast,
in the FC I and FC II state, the use of monotherapy and
initial combination therapy is much more common
(Figure 1). Similarly, it was observed that the most
widely used pharmacological alternative for the
treatment of PAH in Peru was sildenafil, followed
by the combination of sildenafil + bosentan (Figure
2). Adjuvant treatment in this setting consisted of
anticoagulants, diuretics, and digoxin.
In general, the distribution of the costs of diagnosis,
follow-up and non-pharmacological treatment
within the total cost of treatment remained
constant throughout the different stages of disease
severity. Additionally, it was observed that the cost
of pharmacological therapy constitutes the largest
proportion of the total cost of treatment (Table
2) per year per patient, which, in this case, was $
14,841.7.
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Table 1. Main procedures and laboratories for each treatment step in USD.
Procedure

Quantity

Proportion

Annual cost per patient (PPA)

Left heart catheterization

1

100.0%

$251.48

Pulmonary exploration by ventilation/
perfusion

1

100.0%

$202.07

Transesophageal echocardiography

1

100.0%

$160.73

MRI of the heart

1

37.6%

$157.49

Pulmonary angiography

1

37.6%

$86.42

Computed tomography

1

93.0%

$85.43

Right heart catheterization

1

100.0%

$57.41

X-ray of chest

1

100.0%

$47.65

DLCO (Carbon monoxide pulmonary
diffusion test)

1

93.0%

$45.92

Electrocardiogram

1

100.0%

$29.85

Other procedures

1

--

$205.46

Transesophageal echocardiography

1,5

100.0%

$241.10

brain natriuretic

2,5

100.0%

$107.63

2

100.0%

$99.89

right heart catheterization

1,5

100.0%

$86.11

Electrocardiogram

1,5

100.0%

$74.63

Ionogram

2,5

100.0%

$47.36

Diagnostic procedures

ORIGINAL PAPER

Outpatient follow-up

thyroid function test

Hematocrit

2

100.0%

$34.44

1,5

100.0%

$26.69

Serum iron

2

100.0%

$26.41

Prothrombin time

3

100.0%

$18.94

Other procedures

--

100.0%

$89.66

Headache

1

44.3%

$0.49

Elevation of transaminases

1

44.4%

$0.49

Hypotension

1

11.2%

$0.12

Physical rehabilitation therapy

1.6

100.0%

$121.0

Consultation with a PAH specialist

5.3

100.0%

$61.1

Psychological assistance

2.6

100.0%

$34.6

Consultation with other specialists

2

100.0%

$22.8

Immunization against pneumococcal
disease

1

67.2%

$18.6

1.7

100.0%

$13.6

Iron supplementation for anemia

1

34.0%

$3.5

Oxygen therapy

1

25.9%

$1,2

6MWT: Test 6 minute walk

Adverse events

Other follow-ups and outpatient treatments

Social assistance

PPA: purchasing power parity

https://inicib.urp.edu.pe/rfmh/vol21/iss3/16
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Table 2. Distribution of annual treatment cost per pah patient in peru in USD.
Item

Total Cost (PPA)

Percentage

$1.329.9

8.96%

Outpatient follow-up

$852.9

5.75%

Other follow-up and outpatient treatments

$276.4

1.86%

Adjuvant treatment

$148.8

1.00%

hospital treatment

$91.0

0.61%

Transplantation

$12.7

0.09%

Adverse events

$1.1

0.01%

Pharmacological treatment

$12.128.9

81.72%

Total

$14.841.7

100.0%

Diagnosis

ORIGINAL PAPER

HAP: Pulmonary arterial hypertension PPA: Purchasing.power parity.

Graphic 1. Distribution of treatment regimens across functional states.

Graphic 2. Use of pharmacological therapies indicated in PAH.
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DISCUSSION
LInformation regarding the economic impact of
PAH in Peru is scarce. However, this study makes it
possible to establish clear treatment patterns and
some relevant cost-generating events within the
management stages of this pathology. Similarly, it
is evidenced that most patients are in a moderate
stage of the disease, specifically in stages FC II and
FC III, in which the evidence indicates that there is a
significantly different survival prognosis(18).

Early diagnosis continues to be the best alternative
to improve the prognosis of patients since drugs
are available locally for the early stages of the
disease. However, it is known that even in developed
countries the delay in diagnosis ranges around 2
years(21), for which early stratification is the next
decision to be taken, there is evidence even in
patients with FC III and high risk where the Early
and effective pharmacological intervention reduces
rehospitalization and disease progression(20).
Finally, for patients diagnosed in advanced stages,
resources should be directed to specialized centers
of reference, where the opportunity is given to
administer parenteral drugs in a protocolized
manner, which allows the stabilization of the patient
and subsequent overlap with oral drugs that facilitate
their treatment, administration, and adherence.
Pulmonary arterial hypertension (PAH) is a rare
disease and, at the same time, generates a high
https://inicib.urp.edu.pe/rfmh/vol21/iss3/16
DOI: https://doi.org/10.25176/RFMH.v21i3.3905

Retrospective studies have analyzed the costs
of health care and medical resources used in the
diagnosis of PAH in the United States, Copher et al.,(24)
estimated costs since diagnosis, reporting 8,187 US
dollars (USD) per month, 94% of The patients were
on monotherapy (Sildenafil or Bosentan), being
necessary to titrate the therapy in 13% of them,
given this trend established in the treatment routine,
Sikirica et al.,(25) estimated costs during the diagnosis
process (visit index) and 12 months later, the changes
in treatment were: titration, change of medication or
discontinuation. The costs at this time estimated per
year were 116,681 and 98,243 USD in the index visits
and in the follow-up respectively, the decrease of
these estimates was despite an increase in the cost
of the drugs used (Sildenafil, Bosentan, Ambrisentan,
Tadalafil, Iloprost Treprostinil, and Epoprostenol),
they postulated that the result was due to the
reduction in hospital costs, which were significantly
reduced (81,577 USD and 26,297 USD at the baseline
and follow-up visit respectively). This association
was observed more recently in the study by Burger
et al.,(26), with a greater number of patients included,
where a greater than 50% reduction in the frequency
of hospitalization for pulmonary hypertension
was evidenced after initiating specific vasodilator
therapy. Hospitalization is a prognostic variable that
is currently used to measure in studies of pulmonary
arterial hypertension, not only because of the high
incidence described and the costs involved(22), but
also because it is a factor that increases the mortality
rate(27).

ORIGINAL PAPER

The drugs used in patients with functional classes
I and II agree with the norms in international
guidelines. However, a group of patients that even
in functional class II requires therapy with drugs
that use the prostaglandin pathway, specifically an
agonist of selective IP receptors that have shown a
reduction in morbidity and mortality in this phase(19).
In patients with functional class III and IV, there
are still cases with the use of monotherapy, which
reveals the limited access to recommended drugs
at this level of the disease. Also, even when most
patients have indicated sequential therapy, it is
restricted mostly to Sildenafil and Bosentan (Figure
2), making clear the risk of disease progression in
advanced stages given the need for prostaglandin
analogs in this group of patients. Of special attention
is the group of patients in functional class IV, who
have a high risk of death or require transplantation.
The indication of prostaglandin analogs should be
administered parenterally(20), drugs that are not yet
available in the national market.

cost that can be analyzed from different aspects
of the disease. The rapid progression towards
hospitalization and premature death in young
adults is definitely reflected in high hospitalization
rates, Lacey et al.,(22) reported that more than 75%
of PAH patients were hospitalized within the first
year of diagnosis (mean hospital stay: 11 days), of
which 20% were readmitted again within 30 days
(mean hospital stay 24.5 days)(23), which significantly
increases the cost of treatment. The advance in
treatment, with the development of new molecules
that reduce hospitalization and stop the progression
of the disease, is also related to a high cost. The
analysis focuses on establishing whether the new
therapies impact reducing the costs progression of
the disease.

The low-risk profile is the goal to be achieved
in patients with PAH(28). The goal is to avoid
hospitalization as a proxy for mortality, for which
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treatment adherence is essential. Some instruments
allow it to be measured, such as the Morisky Scale
or the Proportion of days covered; Under these
scales, patients with PAH generally show favorable
adherence values(29,30). However, these could be
affected by multiple factors, such as the need to use
more than 1 drug, requiring multiple daily doses,
or having PAH associated with connective tissue
diseases. The presence of comorbidities is a factor
in favor of adherence to multiple pharmacological
therapies(29). Other clinical variables considered were
the presence of adverse events and hospitalization,
which were associated with lower compliance with
treatment(30,31). The cost is not mentioned within the
related factors, but it is mentioned that more than
95% of the patients have financial support from
different assistance programs or foundations(30).
Among the limitations of this study is the use
of the opinion of clinical experts as the primary
source of information since the estimates made
could be biased towards the clinical practice of
these specialists and do not reflect the real-world
scenario in this pathology. Similarly, since the only
specialty consulted for this study was cardiology,
the characteristics described of the patients in this
research could only reflect those of the patients who

Hernández F et al

attend cardiology to treat this condition. On the
other hand, considering that the experts consulted
have extensive experience in the treatment of PAH,
the use of resources and the patient's time probably
correspond to the ideal or recommended course
of treatment for these patients; however, in the
real world, many patients may not arrive quickly
for consultation with a PAH specialist, so their use
of resources and treatment alternatives may differ
significantly from the estimates presented in this
study.
Finally, this reality prompts us to do more outreach
and education about this disease towards an
increasingly early diagnosis that improves the
prognosis of patients. It alleviates the economic
burden on the health systems that assume the
financing of health programs.

CONCLUSION
This study shows that patients with greater
functional impairment (functional class III and IV)
mostly require combined therapy. Because they are
more likely to be hospitalized even with a longer
stay, a higher cost is generated not only due to the
use of drugs but also due to the use of drugs due to
hospital causes.
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